Jeffrey Phillips, MD
Neurology · Yuba City, CANPI 1841362647
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by EMD Serono, Inc. at 39.9% of the total. Reporting peaked in 2021 at $587 and has fallen 57.2% since, to $251 in 2025.
Across 130 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$785
- AbbVie$287
- Genentech USA, Inc.$186
- Biogen$147
- Lilly USA, LLC$128
- Livanova USA, Inc.$67
- plus $368 from 13 others
What the payments were for
- Food & beverage$1,968100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 71 | $785 |
| AbbVie | 16 | $287 |
| Genentech USA, Inc. | 7 | $186 |
| Biogen | 8 | $147 |
| Lilly USA, LLC | 4 | $128 |
| Livanova USA, Inc. | 5 | $67 |
| Bristol Myers Squibb | 3 | $60 |
| Mallinckrodt Enterprises LLC | 3 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Genentech, Inc. | 1 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Forte Bio-pharma LLC | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Catalyst Pharmaceuticals, Inc. | 1 | $20 |
| MDD US Operations, LLC | 1 | $19 |
| Organon | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$1,968 in reported general payments places this provider in the 55th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 66 | $7,424 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 226 | $6,594 |
| Lacosamide | 31 | $2,772 |
| Divalproex Sodium ErDivalproex Sodium | 26 | $1,820 |
| Celecoxib | 20 | $1,763 |
| Levetiracetam | 39 | $1,581 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 44 | $1,466 |
| Morphine Sulfate ErMorphine Sulfate | 24 | $911 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 57 | $819 |
| Sumatriptan Succinate | 12 | $711 |
| Topiramate | 41 | $617 |
| ClopidogrelClopidogrel Bisulfate | 53 | $553 |
| Pregabalin | 15 | $516 |
| Fentanyl | 12 | $504 |
| Carbamazepine | 27 | $442 |
Paid to pharmacies, not to this prescriber.
Other neurology in Yuba City
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.